{"id":"NCT01017120","sponsor":"Stiefel, a GSK Company","briefTitle":"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne","officialTitle":"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-01","primaryCompletion":"2010-11-01","completion":"2010-11-09","firstPosted":"2009-11-20","resultsPosted":"2012-07-06","lastUpdate":"2017-05-18"},"enrollment":742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Tazarotene Foam","otherNames":[]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.","primaryOutcome":{"measure":"Absolute Change in Lesion Counts (LCs) From Baseline to Week 12","timeFrame":"Baseline (Week 0/Day 1) and Week 12","effectByArm":[{"arm":"Tazarotene Foam","deltaMin":-17.8,"sd":11.81},{"arm":"Vehicle Foam","deltaMin":-14.7,"sd":10.66}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":18,"countries":["United States","Canada"]},"refs":{"pmids":["23652892"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":373},"commonTop":["Application Site Irritation","Application site dryness"]}}